Citations

Mayo Clinic

Showing 10 of 108602 citations.

Needs-based novel digital curriculum for the neuromodulation training deficit: Pain Rounds
Durbhakula, Shravani , Toy, Serkan , Acosta, C. , Barman, Ross , Kelner, Andrew F, Issa, Mohammad A. , Broachwala, Mustafa , Marascalchi, Bryan J. , Navalgund, Yeshvant A, Pak, Daniel , Petersen, Erika , Moeschler, Susan M. , Kohan, Lynn , Barman, Ross A , Mehta, Neel D , Kohan, Lynn R , Acosta, Carlos A

Regional Anesthesia & Pain Medicine | April 13, 2023 | Volume: 48 | Issue: 8 | Pages: 414-419

10.1136/rapm-2023-104480 | PMID 37055185 Get It

This study reports the needs-based development, effectiveness and feasibility of a novel, comprehensive spinal cord stimulation (SCS) digital curriculum designed for pain medicine trainees. The curriculum aims to address the documented systematic variability in SCS education and empower physicians with SCS expertise, which has been linked to utilization patterns and patient outcomes. Following a needs assessment, the authors developed a three-part SCS e-learning video curriculum with baseline and postcourse knowledge tests. Best practices were used for educational video production and test-question development. The study period was from 1 February 2020 to 31 December 2020. A total of 202 US-based pain fellows across two cohorts (early-fellowship and late-fellowship) completed the baseline knowledge assessment, while 122, 96 and 88 participants completed all available post-tests for Part I (Fundamentals), Part II (Cadaver Lab) and Part III (Decision Making, The Literature and Critical Applications), respectively. Both cohorts significantly increased knowledge scores from baseline to immediate post-test in all curriculum parts (p<0.001). The early-fellowship cohort experienced a higher rate of knowledge gain for Parts I and II (p=0.045 and p=0.027, respectively). On average, participants viewed 6.4 out of 9.6 hours (67%) of video content. Self-reported prior SCS experience had low to moderate positive correlations with Part I and Part III pretest scores (r=0.25, p=0.006; r=0.37, p<0.001, respectively). Initial evidence suggests that Pain Rounds provides an innovative and effective solution to the SCS curriculum deficit. A future controlled study should examine this digital curriculum’s long-term impact on SCS practice and treatment outcomes.
Defecatory disorders in patients with type 1 diabetes and chronic constipation
Xiao, Alexander , Ramu, Shivabalan Kathavarayan , Gautam, Misha , Bharucha, Adil E. , Xiao, Alexander H, Kathavarayan Ramu, Shivabalan, Xiao, Alexander H

Neurogastroenterology & Motility | April 13, 2023 | Volume: 35 | Issue: 8 | Pages: No page available

10.1111/nmo.14599 | PMID 37052404 Get It

AbstractBackground and objectivesChronic constipation (CC) may be caused by defecatory disorders (DDs) and associated with reduced rectal sensation. Among patients with type 1 diabetes (T1D) and CC (T1DCC patients), the prevalence of DDs and reduced rectal sensation is unknown. We sought to compare complications of T1D, anorectal dysfunction, and CC symptoms, among T1DCC patients with versus without a DD.MethodsAnorectal pressures at rest and during squeeze and evacuation, as well as rectal sensation and rectal balloon expulsion time (BET) were measured with high‐resolution anorectal manometry in 114 consecutive T1DCC patients.ResultsThirty‐seven patients (32%) had prolonged BET, suggestive of a DD. Complications of T1D included peripheral neuropathy (n = 67, 59%), retinopathy (n = 42, 37%), and nephropathy (n = 26, 23%). Among these complications, only retinopathy was associated with, that is, more prevalent in patients with normal (45%) than prolonged BET (19%). Compared with patients with normal BET, patients with prolonged BET had a lower rectal pressure (mean [SD], 32 [23] mm Hg vs. 23 [19] mm Hg,p = 0.03), greater anal pressure (91 [23] mm Hg vs. 68 [36] mm Hg,p < 0.001), and lower rectoanal gradient (−67 [30] mm Hg vs. −36 [32] mm Hg,p < 0.0001) during evacuation. Anal resting pressure and anal squeeze increment were below normal in 14 (13%) and 32 (29%) of patients and one or more rectal sensory thresholds were above normal in 34 (30%) patients; these abnormalities affected similar proportions in the normal and prolonged BET cohorts.ConclusionsAmong T1DCC patients, 37 (32%) had prolonged BET, which was associated with anorectal pressures indicative of a DD but was not associated with reduced rectal sensation, suggesting that DDs are more likely explained by abdomino‐anal dyscoordination than visceral disturbance.
A Scoping Review of Mobile Apps in Plastic Surgery: Patient Care, Trainee Education, and Professional Development
Jarvis, Nicholas R. , Morris, Bryn E., Verhey, Erik M., Rebecca, Alanna M. , Howard, Michael A., Teven, Chad M. , Jarvis, Tyler

Plastic and Reconstructive Surgery - Global Open | April 13, 2023 | Volume: 11 | Issue: 4 | Pages: e4943

10.1097/gox.0000000000004943 | PMID 37063506 Get It

Background: Over the past 10 years, smartphones have become ubiquitous, and mobile apps serve a seemingly endless number of functions in our everyday lives. These functions have entered the realm of plastic surgery, impacting patient care, education, and delivery of services. This article reviews the current uses of plastic surgery mobile apps, app awareness within the plastic surgery community, and the ethical issues surrounding their use in patient care. Methods: A scoping review of electronically available literature within PubMed, Embase, and Scopus databases was conducted in two waves in November and May 2022. Publications discussing mobile application use in plastic surgery were screened for inclusion. Results: Of the 80 nonduplicate publications retrieved, 20 satisfied the inclusion criteria. Articles acquired from the references of these publications were reviewed and summarized when relevant. The average American Society of Plastic Surgeons evidence rating of the publications was 4.2. Applications could be categorized broadly into three categories: patient care and surgical applications, professional development and education, and marketing and practice development. Conclusions: Mobile apps related to plastic surgery have become an abundant resource for patients, attending surgeons, and trainees. Many help bridge gaps in patient care and surgeon-patient communication, and facilitate marketing and practice development. Others make educational content more accessible to trainees and performance assessment more efficient and equitable. The extent of their impact on patient decision-making and expectations has not been completely elucidated.
Guidelines for the Management of Adult Acute and Acute-on-Chronic Liver Failure in the ICU: Neurology, Peri-Transplant Medicine, Infectious Disease, and Gastroenterology Considerations
Nanchal, Rahul , Subramanian, Ram, Alhazzani, Waleed , Dionne, Joanna C. , Peppard, William , Truwit, Jonathon D. , Al‐Khafaji, Ali , Killian, Alley , Alquraini, Mustafa , Alshammari, Khalil, Alshamsi, Fayez , Cartin‐Ceba, Rodrigo , Hollenberg, Steven M. , Galusca, Dragos, Hyzy, Robert C., Kandiah, Prem , Kumar, Gagan , Morris, Peter E. , Olson, Jody C. , Sieracki, Rita , Steadman, Randolph H., Karvellas, Constantine , Karvellas, Constantine , Singbartl, Kai , Belley‐Côté, Emilie P. , Huang, David T. , Junek, Mats , Morgan, Rebecca L. , Taylor, Beth

Critical Care Medicine | April 13, 2023 | Volume: 51 | Issue: 5 | Pages: 657-676

10.1097/ccm.0000000000005824 | PMID 37052436 Get It

OBJECTIVES: To develop evidence-based recommendations for clinicians caring for adults with acute liver failure (ALF) or acute on chronic liver failure (ACLF) in the ICU. DESIGN: The guideline panel comprised 27 members with expertise in aspects of care of the critically ill patient with liver failure or methodology. We adhered to the Society of Critical Care Medicine standard operating procedures manual and conflict-of-interest policy. Teleconferences and electronic-based discussion among the panel, as well as within subgroups, served as an integral part of the guideline development. INTERVENTIONS: In part 2 of this guideline, the panel was divided into four subgroups: neurology, peri-transplant, infectious diseases, and gastrointestinal groups. We developed and selected Population, Intervention, Comparison, and Outcomes (PICO) questions according to importance to patients and practicing clinicians. For each PICO question, we conducted a systematic review and meta-analysis where applicable. The quality of evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation approach. We used the evidence to decision framework to facilitate recommendations formulation as strong or conditional. We followed strict criteria to formulate best practice statements. MEASUREMENTS AND MAIN RESULTS: We report 28 recommendations (from 31 PICO questions) on the management ALF and ACLF in the ICU. Overall, five were strong recommendations, 21 were conditional recommendations, two were best-practice statements, and we were unable to issue a recommendation for five questions due to insufficient evidence. CONCLUSIONS: Multidisciplinary, international experts formulated evidence-based recommendations for the management ALF and ACLF patients in the ICU, acknowledging that most recommendations were based on low quality and indirect evidence.
Mid-term Renal and Mesenteric Artery Outcomes During Fenestrated and Branched Endovascular Aortic Repair for Complex Abdominal and Thoracoabdominal Aortic Aneurysms in the United States Aortic Research Consortium
Tenorio, Emanuel R. , Schanzer, Andres , Timaran, Carlos H. , Schneider, Darren B. , Mendes, Bernardo C. , Eagleton, Matthew J. , Parodi, Federico E., Gasper, Warren J. , Sweet, Matthew P. , Huang, Ying , Tenorio, Emanuel R , Schneider, Darren B , Farber, Mark , Beck, Adam W , Oderich, Gustavo S.

Annals of Surgery | April 13, 2023 | Volume: 278 | Issue: 4 | Pages: e893-e902

10.1097/sla.0000000000005859 | PMID 37051912 Get It

Objective: To report mid-term outcomes of renal-mesenteric target arteries (TAs) after fenestrated-branched endovascular aortic repair (FB-EVAR) of complex abdominal and thoracoabdominal aortic aneurysm. Background: TA instability (TAI) is the most frequent indication for reintervention after FB-EVAR. Methods: Data from consecutive patients enrolled in 9 prospective nonrandomized physician-sponsored investigational device exemption studies between 2005 and 2020 were reviewed. TA outcomes through 5 years of follow-up were analyzed for vessels incorporated by fenestrations or directional branches (DBs), including TA patency, endoleak, integrity failure, reintervention, and instability. Results: A total of 1681 patients had 6349 renal-mesenteric arteries were targeted using 3720 fenestrations (59%), 2435 DBs (38%), and 194 scallops (3%). Mean follow was 23 ± 21 months. At 5 years, TAs incorporated by fenestrations had higher primary (95 ± 1% vs 91 ± 1%, P < 0.001) and secondary patency (98 ± 1% vs 94 ± 1%, P < 0.001), and higher freedom from TAI (87 ± 2% vs 84 ± 2%, P = 0.002) compared with TAs incorporated by DBs, with no differences in other TA events. DBs targeted by balloon-expandable stent-grafts had significantly lower freedom from TAI (78 ± 4% vs 88 ± 1%, P = 0.006), TA endoleak (87 ± 3% vs 97 ± 1%, P < 0.001), and TA reintervention (83 ± 4% vs 95 ± 1%, P < 0.001) compared with those targeted by self-expandable stent-grafts Conclusions: Incorporation of renal and mesenteric TA during FB-EVAR is safe and durable with high 5-year patency rates and low freedom from TAI. DBs have lower patency rates and lower freedom from TAI than fenestrations, with better performance for self-expandable stent grafts as compared with balloon-expandable stent grafts.
Buspirone for early satiety and symptoms of gastroparesis: A multi‐centre, randomised, placebo‐controlled, double‐masked trial ( BESST )
Parkman, Henry P. , Yates, Katherine P. , Sarosiek, Irene , Bulat, Robert, Koch, Kenneth L. , Grover, Madhusudan , Farrugia, Gianrico , Silver, Paul J., Abdullah, Amirah, Maurer, Alan H. , Malik, Zubair , Miriel, Laura , Tonascia, James , Hamilton, Frank A., Pasricha, Pankaj J. , McCallum, Richard W. , Grover, Madhusudan , Farrugia, Gianrico , Parkman, H P , Abell, Thomas L. , Kuo, Braden , Silver, Paul

Alimentary Pharmacology & Therapeutics | April 13, 2023 | Volume: 57 | Issue: 11 | Pages: 1272-1289

10.1111/apt.17479 | PMID 37052334 Get It

Summary Background Patients with gastroparesis and related disorders have symptoms including early satiety, postprandial fullness and bloating. Buspirone, a 5‐HT 1 receptor agonist, may improve fundic accommodation. Aim To determine if buspirone treatment improves early satiety and postprandial fullness in patients with symptoms of gastroparesis. Methods This 4‐week multi‐centre clinical trial randomised patients with symptoms of gastroparesis and moderate‐to‐severe symptoms of fullness (Gastroparesis Cardinal Symptom Index [GCSI] early satiety/postprandial fullness subscore [ES/PPF]) to buspirone (10 mg orally) or placebo three times per day. The primary outcome was a change in the ES/PPF from baseline to 4 weeks. The primary analysis was per protocol intention‐to‐treat ANCOVA of between‐group baseline vs. 4‐week differences (DoD) in ES/PPF adjusted for baseline ES/PPF. Results are reported using both nominal and Bonferroni (BF) p values. Results and conclusions Ninety‐six patients (47 buspirone, 49 placeboes; 92% female, 50% delayed gastric emptying, 39% diabetic) were enrolled. There was no between‐groups difference in the 4‐week ES/PPF primary outcome: −1.16 ± 1.25 (SD) on buspirone vs −1.03 ± 1.29 (SD) on placebo (mean DoD: −0.11 [95% CI: −0.68, 0.45]; p = 0.69). Buspirone performed better than placebo in patients with severe‐to‐very severe bloating at baseline compared to patients with none to moderate: (ES/PPF DoD = −0.65 vs. 1.58, p TX*GROUP = 0.003; p BF = 0.07). Among individual GCSI symptoms, only bloating appeared to improve with buspirone vs. placebo. Conclusions Patients with moderate‐to‐severe early satiety/postprandial fullness and other symptoms of gastroparesis did not benefit from buspirone treatment to improve the ES/PPF primary outcome compared with placebo. There was a suggestion of the benefit of buspirone in patients with more severe bloating. Trial Registration: ClinicalTrials.gov NCT0358714285.
Characterization of recurrence patterns and outcomes of medulloblastoma in adults: The University of Texas MD Anderson Cancer Center experience
Gregory, Timothy A. , Mastall, Max , Lin, Heather , Hess, Kenneth R. , Yuan, Ying , García, Manuela Martín-Bejarano , Alfaro, Kristin D, Gule-Monroe, Maria , Khatua, Soumen , Rao, Ganesh , Sandberg, David I. , Yeboa, D.N. , McGovern, Susan L. , Zaky, Wafik , Mahajan, Anita , Suki, Dima , Weathers, Shiao‐Pei , Puduvalli, Vinay K. , Peñas-Prado, Marta , Majd, Nazanin , Puduvalli, Vinay K , Fuller, Gregory N. , Huse, Jason T. , Wefel, Jeffrey S. , Paulino, Arnold C. , Harrison, Rebecca A , Groot, John de

Neuro-Oncology Advances | April 13, 2023 | Volume: 5 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdad032 | PMID 37114244 Get It

Abstract Background Medulloblastoma in adults is rare and treatment decisions are largely driven from pediatric literature. We sought to characterize recurrent medulloblastoma in adults. Methods From a single-institution dataset of 200 adult patients diagnosed with medulloblastoma during 1978–2017, those with recurrence were analyzed for clinical features, treatment, and outcome. Results Of the 200 patients, 82 (41%) with median age of 29 years (18–59) had recurrence after a median follow-up time of 8.4 years (95% CI = 7.1, 10.3). Of these, 30 (37%) were standard-risk, 31 (38%) were high-risk, and 21 (26%) had unknown-risk diseases at the time of initial diagnosis. Forty-eight (58%) presented with recurrence outside the posterior fossa, of whom 35 (43%) had distant recurrence only. Median Progression-free survival (PFS) and OS from initial surgery were 33.5 and 62.4 months, respectively. Neither PFS nor OS from initial diagnosis differed between the standard-risk and high-risk groups in those who experience recurrence (P = .505 and .463, respectively). Median OS from first recurrence was 20.3 months, also with no difference between the standard-risk and high-risk groups (P = .518). Recurrences were treated with combinations of re-resection (20 patients; 25%), systemic chemotherapy (61 patients; 76%), radiation (29 patients; 36%), stem cell transplant (6 patients; 8%), and intrathecal chemotherapy (4 patients; 5%). Patients who received radiation at recurrence had better OS (32.9 months) than those who did not (19.2 months) (P = .034). Conclusions Recurrent medulloblastoma in adults has a poor prognosis irrespective of initial risk stratification. Recurrence commonly arises outside the posterior fossa years after initial diagnosis.
Clinical features and outcomes of high grade serous ovarian cancer (HGSOC) in Asian Indians and Pakistani Americans (AIPA)
Gaire, Suman , Budhathoki, Pravash , Shah, Anish , Karki, Ujjwal , Yadav, Siddhartha

International Journal of Cancer Care and Delivery | April 13, 2023 | Volume: 3 | Issue: Supplement 1 | Pages: No page available

10.53876/001c.73636 Get It

Mycolactone: A Broad Spectrum Multitarget Antiviral Active in the Picomolar Range for COVID-19 Prevention and Cure
Asiedu, Seth O. , Gupta, Yash , Nicolaescu, Vlad , Gula, Haley , Caulfield, Thomas R. , Durvasula, Ravi , Kempaiah, Prakasha , Kwofie, Samuel K., Wilson, Michael D. , Asiedu, Seth Osei , Kwofie, Samuel K , Caulfield, Thomas R , Kempaiah, Prakasha , Gupta, Yash

International Journal of Molecular Sciences | April 13, 2023 | Volume: 24 | Issue: 8 | Pages: 7151

10.3390/ijms24087151 | PMID 37108313 Get It

We have previously shown computationally that Mycolactone (MLN), a toxin produced by Mycobacterium ulcerans, strongly binds to Munc18b and other proteins, presumably blocking degranulation and exocytosis of blood platelets and mast cells. We investigated the effect of MLN on endocytosis using similar approaches, and it bound strongly to the N-terminal of the clathrin protein and a novel SARS-CoV-2 fusion protein. Experimentally, we found 100% inhibition up to 60 nM and 84% average inhibition at 30 nM in SARS-CoV-2 live viral assays. MLN was also 10× more potent than remdesivir and molnupiravir. MLN’s toxicity against human alveolar cell line A549, immortalized human fetal renal cell line HEK293, and human hepatoma cell line Huh7.1 were 17.12%, 40.30%, and 36.25%, respectively. The cytotoxicity IC50 breakpoint ratio versus anti-SARS-CoV-2 activity was more than 65-fold. The IC50 values against the alpha, delta, and Omicron variants were all below 0.020 µM, and 134.6 nM of MLN had 100% inhibition in an entry and spread assays. MLN is eclectic in its actions through its binding to Sec61, AT2R, and the novel fusion protein, making it a good drug candidate for treating and preventing COVID-19 and other similarly transmitted enveloped viruses and pathogens.
BTK Inhibitors and Other Targeted Therapies in Waldenström Macroglobulinemia
Chohan, Karan , Kapoor, Prashant , Chohan, Karan L

Hemato | April 13, 2023 | Volume: 4 | Issue: 2 | Pages: 135-157

10.3390/hemato4020012 Get It

Waldenström macroglobulinemia (WM) is a rare, non-Hodgkin lymphoma that remains incurable. Rituximab, an anti-CD20 monoclonal antibody has been the cornerstone of treatment against WM, and its combination with an alkylator, bendamustine, achieves durable remission in treatment-naive patients with symptomatic WM. However, novel “druggable” targets that have been identified within the clonal lymphoplasmacytic cells in WM have resulted in a rapid development of targeted therapies in both the frontline and relapsed and refractory (R/R) settings. Several agents directed against the known targets have shown promising efficacy, with mostly manageable toxicities. The class of Bruton’s tyrosine kinase (BTK) inhibitors has transformed the therapeutic landscape for patients with WM, given their convenient oral dosing and strong efficacy, with high rates of attainment of very good partial response (VGPR). The tolerability of the next-generation BTK inhibitors appears to be superior to that of the first-in-class agent, ibrutinib. Targeted therapies from other classes have also demonstrated efficacy in both single-agent and combination regimens. Inhibitors of proteasome BCL-2, mTOR and PI-3 kinase have demonstrated efficacy in WM. Emerging therapies under investigation will continue to further shape the management paradigm, especially in the R/R setting. These include bispecific antibodies, radiotherapeutic agents and chimeric antigen receptor T-cell (CART) cell therapies. This review outlines the current literature and future direction of targeted therapies in WM.